Cellectar Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 91 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.67.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Cellectar Biosciences Inc is 7.19, ranking 118 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.
Key Metrics
The current valuation score of Cellectar Biosciences Inc is 8.85, ranking 4 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -0.32, which is -149.01% below the recent high of 0.16 and -146.84% above the recent low of -0.80.
The current earnings forecast score of Cellectar Biosciences Inc is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 76.00 and a low of 18.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Cellectar Biosciences Inc is 6.65, ranking 86 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 3.22 and the support level at 2.41, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Cellectar Biosciences Inc is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 10.12%, representing a quarter-over-quarter decrease of 25.29%. The largest institutional shareholder is The Vanguard, holding a total of 89.12K shares, representing 2.10% of shares outstanding, with 43.75% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Cellectar Biosciences Inc. The Pharmaceuticals industry's average is 5.19. The company's beta value is 0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
